Doubling Down: Brandon Barniea Bets Big on Combination Therapy
Brandon Barniea didn’t believe he needed to visit doctors. The athletic 35-year-old had always been healthy – even when his wife and two kids were sick at home with the flu, he would miraculously avoid falling ill. So, when he found what felt like “beads” in his neck, reality came crashing in; following a biopsy, he was diagnosed first with stage III melanoma in August 2015 and later that year it progressed to stage IV.
L’Oréal Paris USA-MRA Team Scientists shed light on how melanoma spreads
By Kristen Mueller, Ph.D., MRA Scientific Program Director | 29 August 2017 In Allies & Partnerships, Science, Treatment
MRA is extremely proud of the 289 investigators we have funded over the last decade and the exciting advances they have made toward ending suffering and death due to melanoma. While we can never highlight all of them at one time, we’re excited in this blog to highlight the work of the L’Oreal Paris USA sponsored MRA Team award.
MRA Announces its Tenth Annual Request for Proposals
By Kristen Mueller, Ph.D., MRA Scientific Program Director | 14 August 2017 In News, Science, Treatment
MRA is pleased to announce our 2017/18 Request for Proposals (RFP). As in prior years, MRA seeks high-impact pre-clinical, translational, and early clinical research that has the potential to lead to near-term impact in melanoma prevention, detection, diagnosis, staging, and treatment.
Why so much excitement about CAR-T cells?
By Kristen Mueller, Ph.D., MRA Scientific Program Director | 18 July 2017 In News, Science, Treatment
July 12, 2017, marked a historic day for medicine and for the US Food and Drug Administration (FDA) when an expert advisory committee to the FDA unanimously endorsed the first ever genetically engineered, cell-based therapy for use in patients.
Melanoma Treatments: Breakthroughs for Multiple Cancers — for Real and Right Now
By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 10 July 2017 In Science, Treatment
While 2014 and 2015 offered a whirlwind of good news related to new melanoma treatments from immune to targeted therapy, since then, it’s been a bit quieter in melanoma. Although there has been exceptional news in regard to other cancers. Why is that, and what are the latest breakthroughs?
Sunscreen Laws may Hinder Protecting Children from Exposure
With the launch of summer comes conventional discussion around ranking sunscreens, and chatter between the experts to parse what should be considered in choosing the most effective among them. It’s also a key conversation among parents heading into the season with an eye on protecting their children from sun exposure. Yet, something remaining a central concern among those parents is the public policy surrounding use of sunscreen in schools.
Melanoma Research Alliance and the American Cancer Society Forge Research Partnership to Maximize Immunotherapy Benefit to Patients
The Melanoma Research Alliance (MRA) and the American Cancer Society (ACS) are partnering to fund much-needed research aimed at decreasing rare, but serious, side effects associated with checkpoint inhibitors in hopes of increasing further cancer immunotherapy benefit to patients.
MAC: A Valued Partner in the Fight Against Melanoma
What do you do after the melanoma diagnosis has settled in and you’ve done all you can to ensure the best health outcome for yourself? Or even worse, what do you do after you’ve lost a spouse or a child to melanoma? For the members of the Melanoma Action Coalition, the answer is clear. You take that fear or sorrow, and you mobilize.
Non-invasive Detection Modalities and Metastatic Risk Stratification for Melanoma: Where Are We Now?
By Pooja H. Rambhia, MD Candidate, Case Western Reserve University | 10 July 2017 In Prevention, Science, Treatment
While dermatologists have advocated for patient education about irregular skin lesions in order to catch melanomas earlier, dermatologists ultimately play the largest role in the detection and excision of abnormal skin lesions via skin biopsy. However, visual recognition and assessment of pigmented skin lesions is limited to the eye of the dermatologist, and can be challenging for even the most experienced clinicians.
Melanoma Research Alliance Welcomes New Chief Development Officer
Following 22 years of fundraising and management experience in healthcare, higher education and NPOs, Joan Russo is joining the Melanoma Research Alliance (MRA) as Chief Development Officer.